ALOPEXX Oncology

Alopexx Enterprises collaborates with scientists and entrepreneurs to build successful new companies. We invest in novel healthcare technologies at various stages of development, either as the primary investor or in collaboration with a group of investors to advance significant science. We also have the capability to provide management and development expertise when needed. To date, our initial investment range is $1-20 billion. The Alopexx team consists of experts with deep industry knowledge and technical expertise across all areas of drug development, including pharmacology, CMC, toxicology, medicine and clinical operations, quality, and regulatory affairs. We have established partnerships with academic institutions, biotechnology, and pharmaceutical companies to drive our portfolio companies to deliver breakthrough therapies to patients in need. Our business model is to invest and develop up to a crucial inflection point, then partner assets for further development and/or commercialization.